florquinitau F18
Sponsors
Janssen - Cilag International, Alector LLC, Merck Sharp & Dohme LLC
Conditions
Alzheimer's DiseaseAlzheimer’s DiseaseEarly Alzheimer's DiseasePreclinical Alzheimer’s Disease
Phase 2
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease
Active, not recruitingCTIS2022-501188-42-00
Start: 2021-04-15Target: 195Updated: 2025-12-16
A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer's Disease
CompletedCTIS2023-506872-29-00
Start: 2023-04-13End: 2024-11-25Target: 178Updated: 2025-01-22
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer’s Disease
SuspendedCTIS2023-505096-68-00
Start: 2025-01-14Target: 151Updated: 2025-10-30
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease
RecruitingCTIS2024-519190-19-00
Start: 2025-10-03Target: 58Updated: 2025-11-07